Loading insider details...
Beta
Latest Form 4 (Sep 21, 2026): Exercise/Conversion of 6,250 CCCC shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | C4 Therapeutics, Inc. (CCCC) | Exercise/Conversion | 6,250 | n/a |
| Feb 18, 2026 | C4 Therapeutics, Inc. (CCCC) | Grant/Award | 240,000 | n/a |
| Sep 19, 2025 | C4 Therapeutics, Inc. (CCCC) | Exercise/Conversion | 6,250 | n/a |
| Feb 18, 2025 | C4 Therapeutics, Inc. (CCCC) | Tax Withholding | 1,863 | $6.0K |
| Nov 12, 2024 | C4 Therapeutics, Inc. (CCCC) | Exercise/Conversion | 3,750 | n/a |
| Sep 20, 2024 | C4 Therapeutics, Inc. (CCCC) | Tax Withholding | 1,837 | $11.7K |
| Sep 17, 2024 | C4 Therapeutics, Inc. (CCCC) | Exercise/Conversion | 2,250 | n/a |
| Mar 8, 2024 | C4 Therapeutics, Inc. (CCCC) | Disposition to Issuer | 45,000 | n/a |
| Feb 15, 2024 | C4 Therapeutics, Inc. (CCCC) | Tax Withholding | 1,301 | $8.5K |
| Sep 19, 2023 | C4 Therapeutics, Inc. (CCCC) | Grant/Award | 25,000 | n/a |